Enable Injections

10/15/2026

Thank you to everyone who visited our booth and joined our presentations at PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2026 in Palm Springs, CA.

Contact us to learn more about enFuse® On-Body Drug Delivery System: https://enableinjections.com/contact-us/

10/14/2026

As the industry considers more large-volume SC therapies, challenging long-held assumptions could open the door to new possibilities in formulation and device strategy.

A recent ONdrugDelivery article from Enable Injections brings together findings from multiple industry surveys and publications, along with regulatory approvals, to take a closer look at the commonly cited 2-3 mL limit.

The conversation around SC delivery is evolving. Take a closer look at the evidence behind it:

Dr Haydon DuMond, Dr Mehul Desai, along with Dr Shirish Ingawale, examine survey evidence and regulatory precedent showing that the widely cited 2–3 mL limit on subcutaneous delivery reflects device history and information habits rather than tissue biology, and consider the consequences for formul...

10/13/2026

Join us at the Reuters Events: Pharma Customer Engagement USA 2026 to connect with industry leaders and explore the latest trends shaping customer engagement across the pharmaceutical industry.

Don’t miss the chance to meet with recent BioSpace 40 Under 40 Honoree, SVP, Global Medical Affairs & Advocacy Mehul Desai, PharmD, MBA, to learn more about Enable Injections and the enFuse® technology.

To set up a meeting, reach out to Mehul directly on LinkedIn or contact us at: https://enableinjections.com/contact-us/

10/08/2026

Join us at 2026 Partnership Opportunities for Drug Delivery (PODD) Conference by Fierce Pharma in Boston, MA from October 29 – 30 to learn about the latest developments in large volume subcutaneous drug delivery.

Don’t miss the chance to meet with Senior Director, Business Development & Corporate Strategy Bruce Ernest, PharmD, MHA, BSB and explore how these advances can benefit your organization.

Contact us at: https://enableinjections.com/contact-us/ or reach out to Bruce directly on LinkedIn.

10/07/2026

From delivering 5-25 mL in a single device to leveraging original container closure systems, the enFuse® On-Body Delivery System is designed to give pharmaceutical companies flexibility while keeping the injection experience simple for patients.

And as recent regulatory approvals continue to validate on-body delivery for large-volume SC therapies, the path from IV to SC is becoming increasingly tangible.

Learn more about the challenges and opportunities involved in moving complex biologics from IV to SC administration in the September special feature of Drug Development & Delivery: https://drug-dev.com/special-feature-injection-devices-advancements-converge-to-expand-patient-possibilities/

10/06/2026

Congratulations to Mehul Desai, SVP, Global Medical Affairs & Advocacy on being named BioSpace 2026 40 Under 40 honoree!

This recognition highlights Mehul’s contributions to advancing the understanding of large-volume subcutaneous drug delivery and generating research on stakeholder preferences for on-body delivery.

Congratulations Mehul, on this well-deserved achievement!

Read the full article here: https://www.biospace.com/business/biospace-40-under-40-winners-make-their-mark-on-biopharma

10/05/2026

Join Our Team!

We're hiring and looking for individuals to be part of our growing organization. If you're ready for a new opportunity and want to make an impact with a team that values collaboration, innovation, and continuous growth, we'd love to connect with you.

Explore our current openings and apply here: https://vist.ly/5m32g

10/01/2026

What happens when technology and biology converge in oncology?

In Lumanity’s recent webinar, “Localized & Systemic Effects in Oncology: Where Technology & Biology Intersect,” Enable’s Chief Commercial Officer, Matt Huddleston, joined industry experts for a conversation on the evolving oncology landscape and the opportunities that emerge when technology meets biology.

If you missed the live discussion, catch the full webinar here: https://event.on24.com/eventRegistration/console/apollox/mainEvent?&eventid=5428414&sessionid=1&username=&partnerref=Website&format=fhvideo1&mobile=&flashsupportedmobiledevice=&helpcenter=&key=B1421361A2C30007737553658CA29467&newConsole=true&nxChe=true&newTabCon=true&consoleEarEventConsole=true&consoleEarCloudApi=false&text_language_id=en&playerwidth=748&playerheight=526&eventuserid=842980415&contenttype=A&mediametricsessionid=733712455&mediametricid=7586987&usercd=842980415&mode=launch

09/29/2026

We’re proud to partner with Roche on a new subcutaneous formulation for patients living with multiple sclerosis for at-home administration using an on-body injector based on enFuse® technology. We look forward to progressing this partnership with the aim of increasing patient comfort and convenience.

09/28/2026

Sometimes the most innovative part of a drug delivery system is the one that patients never see.

The enFuse® On-Body Drug Delivery System features a hidden, retractable needle designed to remain out of sight throughout the entire administration process. This unique design approach can help address important considerations in the subcutaneous injection experience.

Explore the technology behind the enFuse system here: https://vist.ly/5k6jx